Locations:
SearchLearn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies
Leukemia, Chronic Myeloid (CML)
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
ARIA 2915 | 15-875
View full trial information.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Renal
A Phase Ib Trial of Neoadjuvant Durvalumab +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
CASE 12815 | 16-558
View full trial information.
NSCLC (Non-small cell lung cancer)
A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects
MRK 1516 | 16-1153
View full trial information.
All Cancer Types
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
JAN 1Y16 | 16-694
View full trial information.
Solid Tumors
Feasibility of Tumor Genomic Sequencing Using the Tempus Platform
CASE 6Y16 | 16-1350
View full trial information.
Search our Cancer Clinical Trials database for a full listing of all open and accruing studies:clevelandclinic.org/CancerClinicalTrials.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy